A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects
- Registration Number
- NCT02289599
- Lead Sponsor
- Eisai Co., Ltd.
- Brief Summary
This study will be a single-center, single dose, randomized, double-blind, placebo-controlled study in healthy Japanese male subjects. The study will consist of 2 parts: Part A (young subjects) and Part B (elderly subjects). In Part A sequential cohorts of subjects will be treated with single ascending doses of E2307. The maximum tolerated dose (MTD) will be determined in Part A. Part B will be initiated after Part A is completed. In Part B one cohort of healthy elderly subjects will be treated with a single dose of E2307 at one dose level below the MTD. In part A, a total of 56 subjects will be enrolled into 7 cohorts sequentially and randomized 3:1 to receive either E2307 (1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 200 mg, or 300 mg) or placebo. In part B, a total of 8 subjects will be randomized, 6 subjects to a single dose of E2307 and 2 subjects to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 24
Parts A and B
-
Provide written informed consent
-
Willing and able to comply with all aspects of the protocol
Part A: Young cohort
-
Non-smoking, male subjects age >=20 years and less than 55 years old at the time of informed consent
Part B: Elderly Cohort
-
Non-smoking, male subjects age >=65 years and less than 85 years old at the time of informed consent
Subjects who meet any of the following criteria will be excluded from this study:
- Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- Any history of abdominal surgery that may affect PK profiles of E2307 (eg. hepatectomy, nephrectomy, digestive organ resection)
- Known history of clinically significant drug allergy (at Screening)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part A: 10 mg E2307 (young cohort) E2307 E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 10 mg E2307 (young cohort) E2307 Matching Placebo E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 1 mg E2307 (young cohort) E2307 E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 1 mg E2307 (young cohort) E2307 Matching Placebo E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 3 mg E2307 (young cohort) E2307 E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part A: 3 mg E2307 (young cohort) E2307 Matching Placebo E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part A: 30 mg E2307 (young cohort) E2307 E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part A: 30 mg E2307 (young cohort) E2307 Matching Placebo E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part A: 100 mg E2307 (young cohort) E2307 E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 100 mg E2307 (young cohort) E2307 Matching Placebo E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule) Part A: 200 mg E2307 (young cohort) E2307 E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules) Part A: 200 mg E2307 (young cohort) E2307 Matching Placebo E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules) Part A: 300 mg E2307 (young cohort) E2307 E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part A: 300 mg E2307 (young cohort) E2307 Matching Placebo E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules) Part B: Elderly cohort E2307 One dose level below MTD from Part A
- Primary Outcome Measures
Name Time Method Plasma PK of E2307: Vz/F (apparent volume of distribution at terminal phase) Up to 12 days Vz/F are calculated for E2307 only
Plasma PK of E2307: AUC ratio (AUC ratio of metabolite to parent) Up to 12 days Urine PK of E2307: Ae (cumulative amount of drug excreted in urine up to 264 hours postdose) Up to 12 days Urine PK of E2307: CLR (renal clearance) Up to 12 days Plasma PK of E2307: t1/2 (terminal elimination phase half-life) Up to 12 days Number of adverse events/serious adverse events Up to 30 days Plasma pharmacokinetics (PK) of E2307: Cmax (maximum observed concentration) Up to 12 days Plasma PK of E2307: tmax (time at which the highest drug concentration occurs) Up to 12 days Plasma PK of E2307: AUC(0-t) [area under the concentration (AUC)-time curve from zero time to time of last quantifiable concentration] Up to 12 days Plasma PK of E2307: AUC(0-inf) [area under the concentration-time curve from zero time extrapolated to infinite time] Up to 12 days Plasma PK of E2307: CL/F (apparent total clearance following oral administration) Up to 12 days CL/F are calculated for E2307 only
- Secondary Outcome Measures
Name Time Method Mean difference in change of mean blood pressure (BP) between E2307 and placebo 24 hours predose and continue until 24 hours postdose (Day 2) QT interval assessment using Holter monitoring 24 hours predose through Day 2 (at 24 hours postdose)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.